他汀|从各国血脂指南,看中等强度他汀在中国人群中的地位( 三 )


[2]Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA /ACC/ AACVPR/ AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139(25): e1082-e1143.
[3]Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020, 41(1): 111-188.
[4]Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation, 2007, 115(6):700-707.
[5]Alberton M, Wu P, Druyts E, et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM. 2012, 105(2):145-157.
[6]Sasaki J, Otonari T, Sawayama Y, et al. Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin - effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study). J Atheroscler Thromb. 2012;19(5):485-493.
【他汀|从各国血脂指南,看中等强度他汀在中国人群中的地位】他汀|从各国血脂指南,看中等强度他汀在中国人群中的地位
文章图片

推荐阅读